Dynavax (DVAX) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance
February 23, 2023 4:05 PM EST2022 total revenue of $723 million, up 64% from $439 million in 2021HEPLISAV-B® vaccine net product revenue of $126 million, representing 104% growth compared to 2021CpG 1018® adjuvant vaccine net product revenue of $588 million2023 HEPLISAV-B net product revenue anticipated to be between $165 million and $185 million, representing year-over-year revenue growth of approximately 30-47%Increased strength of financial position with year-end cash and investments of $624 millionConference call today at 4:30 p.m. ET/1:30 p.m. PT
EMERYVILLE, Calif., Feb. 23, 2023 /PRNewswire/ --... More
